CSL Seqirus is a global leader in influenza vaccine production and pandemic preparedness, formed in 2015 following CSL Limited’s acquisition of Novartis’s influenza vaccine business and its combination with BioCSL. The company is dedicated to reducing the severity and impact of influenza, which can cause epidemics and pandemics with significant health consequences. CSL Seqirus produces vaccines that protect millions annually and operates advanced manufacturing facilities in the UK, US, and Australia, utilizing both egg-based and cell-based technologies alongside proprietary adjuvants. Their Liverpool site is the largest vaccine manufacturing facility in the UK and one of the largest in Europe, capable of producing over 50 million doses of seasonal influenza vaccine.
In the EU, CSL Seqirus targets key legislative and policy areas including the EU Health Data Space, EU Health Emergency Response Authority, pharmaceutical legislation, emergency authorization regulations, and agencies like the ECDC and EMA. Their lobbying efforts are conducted in alignment with their mission to support public health through vaccination and pandemic preparedness.
CSL Seqirus engages in networking primarily through its affiliation with Vaccines Europe, a trade association representing vaccine manufacturers. They have actively participated in campaigns such as the EU Flu Day from 2020 to 2024 and sponsored events at the European Parliament focused on healthcare policymaking and real-world evidence. Additionally, they support scientific exchange and education through grants to the European Scientific Working group on Influenza (ESWI).
Financially, CSL Seqirus reported lobbying expenditures in the range of €400,000 to €499,999 for the financial year July 2023 to June 2024. They employed intermediaries such as Acumen Public Affairs, with payments between €100,000 and €199,999 for lobbying services. The company declares a total of 4 lobbyists, equivalent to 1.1 full-time equivalents, involved in their EU lobbying activities. CSL Seqirus has not declared any high-level Commission meetings or meetings with the European Parliament but maintains transparency through the EU Transparency Register.
